Corvus Pharmaceuticals, Inc. (17) | Uncategorized (8)
Recent Contracts
-
Open Market Sale Agreement, dated November 1, 2021, by and between Corvus Pharmaceuticals, Inc. and Jefferies LLC
(Filed With SEC on March 10, 2022)
-
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 25, 2021)
-
Phase I/IB Combination Study Agreement, dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
(Filed With SEC on October 29, 2020)
-
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 9, 2020)
-
Amendment No. 1 to the Phase I/IB Combination Study Agreement, dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
(Filed With SEC on March 9, 2020)
-
Amendment No. 2 to the Phase I/IB Combination Study Agreement, dated August 1, 2019, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
(Filed With SEC on March 9, 2020)
-
Amendment No. 1 to the Phase 1b/II Combination Study Agreement dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
(Filed With SEC on March 9, 2020)
-
Offer Letter, dated as of January 7, 2019 by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher
(Filed With SEC on March 7, 2019)